Search Immortality Topics:

Page 30«..1020..29303132..4050..»


Ultimovacs ASA: Mandatory notification of trades by primary insider

Posted: March 10, 2024 at 3:13 am

Oslo, 9 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider in Ultimovacs ASA, sold on 8 March 2024, 400,000 shares in the company at an average price of NOK 7.8984 per share. Following these transactions, Langøya Invest AS and closely related parties hold 400,000 shares in Ultimovacs ASA.

See more here:
Ultimovacs ASA: Mandatory notification of trades by primary insider

Recommendation and review posted by G. Smith

Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD…

Posted: March 10, 2024 at 3:13 am

– STRIDE Phase 2 primary endpoint of PASI 75 and key secondary endpoints met at all clinically relevant doses tested; sustained maximal target inhibition safely achieved at top dose –

Read the rest here:
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD...

Recommendation and review posted by G. Smith

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Posted: March 10, 2024 at 3:13 am

SAN DIEGO, Calif., March 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, highlights new research that, for the first time, reveals the gene expression profile of seborrheic dermatitis. The Arcutis sponsored research from The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai was presented in a scientific session at the American Academy of Dermatology (AAD) annual meeting (San Diego, CA, March 8 – 12) and answers key questions on the immune response and associated skin barrier disruption of seborrheic dermatitis.

More here:
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Recommendation and review posted by G. Smith

Global Dermatological Drugs Market Set to Surpass US$30 Billion with Advanced Nanotechnology and Aging … – PR Newswire

Posted: March 2, 2024 at 2:40 am

DUBLIN, Feb. 28, 2024 /PRNewswire/ -- The "Dermatological Drugs Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.

World revenue for Dermatological Drugs Market, in terms of value is forecast to surpass US$30 billion in 2024, with strong revenue growth through to 2034.

Geriatric Population Driving Demand for Dermatological Drugs

As the global population ages at an unprecedented pace, the dermatological drugs market is poised for a significant upswing. According to the World Health Organization (WHO), by 2050, 80% of older individuals will reside in low- and middle-income countries. The rapid acceleration in population aging, outpacing historical trends, is a key catalyst. As per WHO, by 2030, one in every 6 person will be aged 60 or over. Also, from 2021 to 2050, population aged over 65 in Asia will grow by more than half-a-billion, creating a burgeoning market for dermatological drugs. This demographic shift signifies an increased demand for skincare solutions tailored to age-related dermatological concerns, such as wrinkles, age spots, and skin conditions prevalent in the elderly. Thus, the coming years will mark a lucrative era for the dermatological drugs industry, driven by the unique needs of the expanding geriatric population.

Nanotechnology in Drug Delivery Could Revolutionize the Dermatological Drugs Market

In the dynamic landscape of dermatology, the integration of cutting-edge technological advancements in drug delivery is poised to propel the market to unprecedented heights. The advent of nanotechnology enables precise targeting of skin cells, enhancing the efficacy of dermatological drugs while minimizing side effects. This revolutionary approach ensures a more tailored and efficient treatment, boosting patient outcomes and satisfaction. Micro-needle technology is reshaping the administration of dermatological drugs. These minimally invasive devices painlessly penetrate the skin, facilitating controlled and sustained release of therapeutic agents. This not only improves patient compliance but also optimizes drug absorption, leading to quicker and more effective results. Several companies are actively researching and developing nanocarriers and smart delivery systems for skincare applications such as NanoVibronix (US) and Nanologica (Sweden).

Furthermore, the incorporation of smart polymers in drug formulations represents a paradigm shift in dermatological treatments. These polymers respond to specific physiological cues, releasing drugs at the right time and in the right amounts. This precision enhances therapeutic outcomes, reduces the frequency of application, and minimizes adverse reactions.

Forecasts to 2034 and other analyses reveal commercial prospects

Segments Covered in the Report

Route of Administration

Disease

Prescription Mode

Distribution Channel

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets.

The report also includes profiles and for some of the leading companies in the Dermatological Drugs Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

In summary, the report provides you with the following knowledge:

Key Topics Covered:

1 Report Overview

2 Executive Summary

3 Market Overview 3.1 Key Findings 3.2 Market Dynamics 3.2.1 Market Driving Factors 3.2.1.1 Increasing Prevalence of Skin Disorders 3.2.1.2 Growing Awareness and Patient Education 3.2.1.3 Globalization and Urbanization 3.2.1.4 Revolutionizing Dermatology: Unleashing Market Growth Through Advanced Drug Delivery Technologies 3.2.1.5 Innovative Breakthroughs: Propelling Dermatological Drugs Market Through Surging R&D Investments 3.2.1.6 Geriatric Population Driving Dermatological Drugs Market 3.2.2 Market Restraining Factors 3.2.2.1 Generic Competition 3.2.2.2 Adverse Effects and Safety Concerns 3.2.2.3 Drug Resistance 3.2.2.4 Non-Pharmacological Options: A Hindrance to Dermatological Drugs Market Growth 3.2.2.5 Limited Reimbursement and Coverage Challenges in Dermatological Drugs Sector 3.2.2.6 Regulatory Approval Process Poses Barriers to Dermatological Drugs Market Growth 3.2.3 Market Opportunities 3.2.3.1 Approval of Novel Dermatological Drugs 3.2.3.2 Advancements in Dermatology Research and Technology 3.2.3.3 Telemedicine and E-Health 3.3 COVID-19 Impact Analysis 3.4 Porter's Five Forces Analysis 3.5 PEST Analysis

4 Dermatological Drugs Market Analysis by Route of Administration

5 Dermatological Drugs Market Analysis by Disease

6 Dermatological Drugs Market Analysis by Prescription Mode

7 Dermatological Drugs market Analysis by Distribution Channel

8 Dermatological Drugs Market Analysis by Region

9 North America Dermatological Drugs Market Analysis

10 Europe Dermatological Drugs Market Analysis

11 Asia Pacific Dermatological Drugs Market Analysis

12 Latin America Dermatological Drugs Market Analysis

13 MEA Dermatological Drugs market Analysis

14 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/icaouj

About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

Read more:
Global Dermatological Drugs Market Set to Surpass US$30 Billion with Advanced Nanotechnology and Aging ... - PR Newswire

Recommendation and review posted by G. Smith

Chiral powers next-generation electronics with nanomaterials as it raises $3.8m – Installation – Installation and AV Technology Europe

Posted: March 2, 2024 at 2:40 am

Nanotechnology companyChiral has announced a $3.8m funding round to address the challenge of silicon-based chip shortages, innovating the way nanomaterials are integrated into devices. Its expertise in nanotechnology, automation, and high-precision robotics is said to be pivotal in the industrys move beyond silicon to the next generation of electronics. The pre-seed funding round was co-led by Founderful (formerly Wingman Ventures) and HCVC and includes grants from ETH Zurich and Venture Kick.

Chipmaking has become one of the worlds most critical technologies in the last two decades. The main driver of this explosive growth has been the continuous scaling of silicon technology (widely known as Moores Law). But these advances in silicon technology are slowing down, as we reach the physical limits of silicon. For this reason, the industry has been investing heavily in nanomaterials like carbon nanotube, graphene and TMDs, which are expected to enable chips with unprecedented functionality. However, making electronic devices with these extremely small materials at speed, with precision, and without compromising on quality has been a long-standing obstacle.

Research has evidenced the use case and impact of nanomaterials across a range of electronics including high-performance transistors, low-power sensors, quantum devices, and many more. However, existing production methods, mostly based on chemistry, are not controllable, which has thus far prevented commercialisation of these devices.

Chiral has built high-speed, automated, robotic machines that integrate nanomaterials into devices. These machines can robotically place micrometer-sized (or even nanometer-sized) materials on small chips. Repeating these motions in a fast and automated manner requires a very high level of engineering, which, when done right, ensures the precision and control that conventional chemistry-based methods lack.

The development of Chirals technology started as a national research project conducted at the Swiss Federal Institutes of Technology (ETH Zurich, EPFL, and Empa), in which the companys co-founders, Seoho Jung, Natanael Lanz, and Andre Butzerin participated as PhD students. After 4 years of R&D, the research team finished its first prototype machine, which was 100 times faster than the other systems available at the time. The immediate reaction of the market to the prototype, which quickly led to the companys first batch of pilot customers, convinced the co-founders that they should continue their activity as a company. They incorporated Chiral in June 2023 as a result.

At Chiral, we are pioneering the next generation of electronic devices across industry, explained Seoho Jung, co-founder and CEO at Chiral. Chipmakers are aware of the potential of nanomaterials and were bringing that potential to life. This funding will accelerate the development of our next machine, which will unlock new market opportunities with its versatility and performance. We are also excited to scale our team to keep up with the growing demand and customer base.

The global nanotechnology market size is projected to grow from $79.14 billion in 2023 to $248.56 billion by 2030, at a CAGR of 17.8% (Fortune business insights research). One of the largest chipmakers in the world, Taiwan Semiconductor Manufacturing Company (TSMC)presented its development roadmapshowing nanomaterial-based transistors as its future architecture.

Were thrilled to join forces with Chiral alongside HCVC, said Pascal Mathis, founding partner at Founderful. Chirals AI- and robotics-based technology lets us envision a future where nanomaterial-based chips are being produced at the scale needed for commercialisation a major bottleneck up until now. We look forward to supporting Seoho, Natanael and Andr in their journey to introduce a new paradigm of chips beyond silicon.

Alexis Houssou, founding partner at HCVC, added:With the current boom in AI applications, we stand at a pivotal moment where the slowdown of Moores law threatens to decelerate the pace of technological progress significantly. The team at Chiral has embarked on a critical mission to pave the way toward a groundbreaking post-silicon era, promising to transcend current limitations and unlock new possibilities for advancement. We couldnt be more excited to support their mission, in collaboration with Founderful, as they build the future of computing infrastructure.

Jung concluded:In the future, it will be normal for electronic devices or chips to contain nanomaterials. The development roadmaps of the worlds leading chipmakers like TSMC, Samsung, and Intel all share our vision. We are confident that Chiral technology will empower the industry to make this transition faster.

See the rest here:
Chiral powers next-generation electronics with nanomaterials as it raises $3.8m - Installation - Installation and AV Technology Europe

Recommendation and review posted by G. Smith

How to watch SpaceX launch Crew-8 astronauts to the space station on March 2 (free livestream) – Space.com

Posted: March 2, 2024 at 2:40 am

SpaceX is poised to launch three astronauts and a Russian cosmonaut to the International Space Station (ISS) this week on the company's Crew-8 mission for NASA.

The crew members' spacecraft, SpaceX's Crew Dragon Endeavor, will ride atop a Falcon 9 rocket on its fifth flight from the historic Launch Complex-39A at NASA's Kennedy Space Center in Florida. Liftoff is currently scheduled for no earlier than Saturday, March 2 at 11:16 p.m. EST (0419 GMT on March 3). Liftoff had been scheduled for early Friday morning (March 1), but bad weather forced a delay.

Crew-8 includes NASA astronauts Matthew Dominick (mission commander), Michael Barratt (mission pilot), Jeanette Epps (mission specialist) and Roscosmos cosmonaut Alexander Grebenkin (mission specialist). The quartet will spend roughly six months aboard the orbital lab, taking part in over 200 research investigations and tending to space station maintenance.

Related: 'It's white-knuckle time:' NASA chief stresses safety for Crew-8 astronaut launch

NASA's broadcast of the Crew-8 launch coverage will begin Saturday at 7:15 p.m. EST (0015 GMT on March 3), and will be available here at Space.com.

Coverage of Crew-8's ride to orbit will involve checkpoints beginning with Falcon 9's main booster returned to SpaceX's landing zone at Cape Canaveral and culminating in the release of Endeavor from Falcon 9's second stage. Following the spacecraft's orbital insertion, the Crew Dragon coverage will then switch to an audio-only feed until the beginning of the rendezvous and docking broadcast.

Approximately two hours after liftoff, NASA is expected to hold a post-launch news conference. The early-morning mission check-in will include NASA's commercial crew program manager Steve Stich and ISS program manager Joel Montalbano, as well as SpaceX director of Dragon mission management Sarah Walker.

This is Montalbano's final crewed mission as ISS program manager. Continuing his service to NASA, Montalbano has been promoted to NASA's deputy associate administer of space operations. NASA announced that Dana Weigel will begin as ISS program manager April 7; Weigel will be the first woman to hold the role.

Once in orbit, Crew-8 will spend a little more than 15 hours catching up to the ISS.

Rendezvous coverage is scheduled to begin at 11:30 a.m. EST (1530 GMT) on Sunday (March 3), about 2.5 hours before docking is expected to take place. Crew Dragon Endeavor is slated to dock to the forward-facing port of the station's Harmony module. Hatch opening will occur about two hours later, after which the current space station crew will come together with members of the newly-arrived Crew-8 for a welcome ceremony a long-standing tradition whenever astronauts first come aboard the ISS.

Crew-8's arrival will also mark the imminent departure of the station's Crew-7 astronauts. NASA astronaut Jasmin Moghbeli,European Space Agency(ESA) astronaut Andreas Mogensen, Japan Aerospace Exploration Agency (JAXA) astronaut Satoshi Furukawa and cosmonaut Konstantin Borisov launched to the ISS aboard SpaceX's Crew Dragon Endurance in August. They'll soon be wrapping up their own six-month stay.

Editor's note: This story was updated at 1:20 a.m. ET on Feb. 29 with news of the launch delay to March 2.

View post:

How to watch SpaceX launch Crew-8 astronauts to the space station on March 2 (free livestream) - Space.com

Recommendation and review posted by G. Smith


Page 30«..1020..29303132..4050..»